Q-omics provides the consensus-scored LMNTD2 profile across patient tissues and cancer cell-line models. LMNTD2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LMNTD2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LMNTD2 RNA expression shows 16,776 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, KIRC, and KIRP as cancer lineages where LMNTD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMNTD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMNTD2 survival associations across molecular data types. LMNTD2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMNTD2 RNA expression–survival associations across cancer types. High LMNTD2 expression shows unfavorable associations in KICH, LGG, KIRC, LAML and PRAD, but favorable associations in BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for LMNTD2 RNA expression.
This table summarizes LMNTD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LMNTD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMNTD2 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, HNSC, STAD and BLCA. The KIRC box plot shows higher LMNTD2 RNA expression in tumor versus normal tissue (log2 FC = +0.835, t-test p < 0.001).
This table shows molecular features associated with LMNTD2 in patient tissues and cancer cell lines. In patient samples, LMNTD2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LMNTD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
